Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May;82(7):825-830.
doi: 10.1007/s40265-022-01713-3.

Faricimab: First Approval

Matt Shirley  1
Affiliations
Review

Faricimab: First Approval

Matt Shirley. Drugs. 2022 May.

Abstract

Faricimab (faricimab-svoa; Vabysmo™) is a bispecific antibody that binds to and inhibits both vascular endothelial growth factor (VEGF)-A and angiopoietin-2 (Ang-2). Administered by intravitreal injection, faricimab is being developed by Roche/Genentech for use in the treatment of retinal vascular diseases. In January 2022 faricimab received its first approvals, in the USA, for use in the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD) or diabetic macular edema (DME). Faricimab has also recently been approved in Japan, and is currently under regulatory review in the EU, for use in nAMD and DME. Phase III clinical development of faricimab for use in the treatment of nAMD, DME, and macular edema due to retinal vein occlusion is continuing in multiple other countries worldwide. This article summarizes the milestones in the development of faricimab leading to these first approvals for nAMD and DME in the USA.

PubMed Disclaimer

References

    1. Adamis AP, Brittain CJ, Dandekar A, et al. Building on the success of anti-vascular endothelial growth factor therapy: a vision for the next decade. Eye (Lond). 2020;34(11):1966–72. - DOI
    1. Baumal CR. Wet age-related macular degeneration: treatment advances to reduce the injection burden. Am J Manag Care. 2020;26(5 Suppl):S103–11. - PubMed
    1. Glassman AR, Wells JA 3rd, Josic K, et al. Five-year outcomes after initial aflibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema (Protocol T extension study). Ophthalmology. 2020;127(9):1201–10. - DOI
    1. Ciulla TA, Pollack JS, Williams DF. Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes. Br J Ophthalmol. 2021;105(2):216–21. - DOI
    1. Heier JS, Singh RP, Wykoff CC, et al. The angiopoietin/Tie pathway in retinal vascular diseases: a review. Retina. 2021;41(1):1–19. - DOI

MeSH terms

LinkOut - more resources